glp 1 new indications Long-term Success of GLP-1s Hinges on More Than Just a Prescription KDIGO 2026: Glucagon-like peptide-1-based therapies

Licensing (Marketing Authorisation): The MHRA has approved: Semaglutide (Wegovy) for adults with BMI 30 kg/m or BMI 27 kg/m with at least one weight-related comorbidity Liraglutide (Saxenda) with similar BMI criteria NHS Access (NICE Guidance): According to NICE guidance (TA664 for semaglutide), NHS-funded treatment is more restricted and typically available for adults with: BMI 35 kg/m with at least one weight-related comorbidity (such as hypertension, type 2 diabetes, dyslipidaemia, obstructive sleep apnoea, or cardiovascular disease) For individuals from Black, Asian, and minority ethnic backgrounds, lower BMI thresholds may apply, recognising that these populations face increased metabolic risk at lower BMI levels

You've seen the research

Zhang C

It is not known if Ozempic passes into your breast milk

[DOI] [PMC free article] [PubMed] [Google Scholar] 138.RCP Royal College of Psychiatrists